Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2723948 | 1.00 | CHRNB2 (0.48) | CHRNB2CHRNA4PRKCZMKNK1HTT | |
| SCHEMBL17123792 | 0.88 | HTT (0.49) | HTTALDH1A1HTR1ASLC6A2PDE3B | |
| Hydrochloric Acid SCHEMBL14861677 | 0.86 | HTT (0.47) | HTTALDH1A1HTR1ASLC6A2PDE3B | |
| SCHEMBL5464152 | 0.81 | CHRNB2 (0.49) | CHRNB2CHRNA4PRKCZMKNK1HTR1A | |
| Hydrochloric Acid SCHEMBL5463046 | 0.79 | CHRNB2 (0.48) | CHRNB2CHRNA4PRKCZMKNK1HTR1A | |
| SCHEMBL5516149 | 0.78 | HTT (0.45) | HTTALDH1A1PDE3BPDE3APDE10A | |
| SCHEMBL23791579 | 0.76 | CHRNB2 (0.43) | CHRNB2CHRNA4PRKCZMKNK1 | |
| SCHEMBL29994416 | 0.75 | CHRNB2 (0.53) | CHRNB2CHRNA4PRKCZMKNK1HTR1A | |
| SCHEMBL3655274 | 0.75 | CHRNB2 (0.53) | CHRNB2CHRNA4PRKCZMKNK1HTR1A | |
| SCHEMBL2269304 | 0.75 | CHRNB2 (0.53) | CHRNB2CHRNA4PRKCZMKNK1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838702-A1 | PYRROLIDYL DERIVATIVES OF HETEROAROMATIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | Pfizer Products Inc. (US) | 2007-10-03 | — | — | EP | claimed |
| WO-2006070284-A1 | PYRROLIDYL DERIVATIVES OF HETEROAROMATIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-07-06 | — | — | WO | claimed |
| WO-2012052556-A1 | NOVEL HALOALKOXYQUINAZOLINES, AND PREPARATION AND USE THEREOF | UNIVERSITÄT LEIPZIG (DE) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012052556-A1 | NOVEL HALOALKOXYQUINAZOLINES, AND PREPARATION AND USE THEREOF | UNIVERSITÄT LEIPZIG (DE) | 2012-04-26 | — | — | WO | disclosed |
| US-20090162286-A1 | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions | PFIZER INC. | 2009-06-25 | — | — | US | disclosed |
| EP-1838702-A1 | PYRROLIDYL DERIVATIVES OF HETEROAROMATIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | Pfizer Products Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| EP-1755611-A1 | PHOSPHODIESTERASE 10 INHIBITION AS TREATMENT FOR OBESITY-RELATED AND METABOLIC SYNDROME-RELATED CONDITIONS | Pfizer Products Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20060183763-A1 | Novel pyrrolidyl derivatives of heteroaromatic compounds | PFIZER INC | 2006-08-17 | — | — | US | disclosed |
| WO-2006070284-A1 | PYRROLIDYL DERIVATIVES OF HETEROAROMATIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006070284-A1 | PYRROLIDYL DERIVATIVES OF HETEROAROMATIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-07-06 | — | — | WO | disclosed |
| WO-2005120514-A1 | PHOSPHODIESTERASE 10 INHIBITION AS TREATMENT FOR OBESITY-RELATED AND METABOLIC SYNDROME-RELATED CONDITIONS | PFIZER PRODUCTS INC. (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183763-A1 | Novel pyrrolidyl derivatives of heteroaromatic compounds | PDE12, PDE4A, PDE7A | CHRNB2 615/4885CHRNA4 316/4885PRKCZ 570/4885 |
| US-20090162286-A1 | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions | PDE5A, PDE12, PDE2A | CHRNB2 1581/4885CHRNA4 967/4885PRKCZ 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.